top of page
  • Writer's pictureNammi Therapeutics

Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of Pancreatic

FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of Pancreatic Cancer. QXL 138AM is a Masked Immunocytokine targeting a masked interferon alpha to the CD138 receptor on the surface of tumor cells.

June 16 2022 - QXL138AM Orphan Drug Designation in Pancreatic Cancer
Download PDF • 393KB

8 views0 comments

Recent Posts

See All


bottom of page